Non-specific and specific active immunotherapy in a B16 murine melanoma system
โ Scribed by J. Avent; C. Vervaert; H. F. Seigler
- Book ID
- 102924981
- Publisher
- John Wiley and Sons
- Year
- 1979
- Tongue
- English
- Weight
- 526 KB
- Volume
- 12
- Category
- Article
- ISSN
- 0022-4790
No coin nor oath required. For personal study only.
โฆ Synopsis
Conflicts amongst reports concerning the efficacy of both nonspecific and specific attempts at immunotherapy may be ascribed to different animal models utilizing tumors of different immunogenicity. We have selected the B 16 mouse melanoma model as the example of a spontaneously occurring neoplasm that is histocompatible with the host and does have tunior-associated antigens. Attempts t o alter tumor growth or survival with nonspecific active imrnunotherapy as well as with specific active irnmunotherapy were not successful. Nonspecific active pre-iimnunization failed t o alter tumor take or growth. Specific active immunotherapy both with and without adjuvant did decrease tumor take and prolong host survival. The effects were increasingly documented at lower tumor cell inoculums and became less apparent with increase in the tumor cell challenge.
๐ SIMILAR VOLUMES
The possibility of active specific immunotherapy using interleukin-1 (IL-1) plus sonicated tumor supernatant (SS) was examined in a murine tumor model. The growth of intraperitoneally or subcutaneously inoculated plasmacytoma MOPC IME, which is syngeneic to BALB/c mice, was significantly suppressed
## BACKGROUND. This study was conducted to document the rate, duration, and type of objective response to active specific immunotherapy with a polyvalent melanoma cell vaccine (PMCV) for patients with in-transit melanoma metastases and to identify any acute or chronic toxic effects of PMCV treatme
Treatments available for metastatic prostate cancer have failed to demonstrate significant curative potential. Current efforts are now directed towards developments of novel strategies for the treatment of metastatic prostate cancer. Cancer immunotherapeutic strategies utilize patient immune system